Related Experiment Videos
[Ciclosporine A-induced gingival hyperplasia]
Vera Lúcia Costa Ramalho1, Horácio José Ramalho, José Paulo Cipullo
1Faculdade de Medicina de São José do Rio Preto, Brasil.
Revista Da Associacao Medica Brasileira (1992)
|July 30, 2003
Summary
Cyclosporine A (CSA), used in transplants and autoimmune diseases, can cause gingival hyperplasia (GH), affecting up to 85% of patients. This review covers the causes, diagnosis, and management of this common side effect.
Area of Science:
- Immunopharmacology
- Oral Medicine
- Transplantation Medicine
Context:
- Cyclosporine A (CSA) is a vital immunosuppressant in organ transplantation and autoimmune disease treatment.
- Increased CSA use correlates with a rise in adverse effects, notably gingival hyperplasia (GH).
- Gingival hyperplasia presents significant challenges, impacting aesthetics, speech, mastication, and dental development.
Purpose:
- To provide a comprehensive overview of cyclosporine A-induced gingival hyperplasia (cGH).
- To explore the etiological factors, histological characteristics, and clinical manifestations of cGH.
- To review current strategies for the prevention and treatment of cGH.
Summary:
- Cyclosporine A-induced gingival hyperplasia (cGH) is a frequent adverse drug reaction with variable prevalence, potentially affecting up to 85% of patients.
- Histological findings in cGH include connective tissue and epithelial changes.
- Management involves addressing etiological factors, preventive measures, and therapeutic interventions.
Impact:
- Highlights the clinical significance of cGH as a common and impactful side effect of CSA therapy.
- Informs clinicians about the multifaceted nature of cGH, from its origins to its management.
- Aims to improve patient outcomes by detailing prevention and treatment options for cGH.